Fluxion Biosciences Awarded National Cancer Institute Grant for Development of Rare Cell Isolation Platform

SAN FRANCISCO--(BUSINESS WIRE)--Fluxion Biosciences, a leading developer of microfluidic systems for cellular analysis in life science research, today announced that it has received a $200K grant from the National Cancer Institute (NCI) for the development of a rare cell isolation platform for diagnostic and research applications. The Phase One Small Business Innovation Research Grant will enable Fluxion to further develop its innovative microfluidic platform. The endpoints of this research include enhanced methods for detecting circulating tumor cells that appear in very low concentrations in the early stages of cancer.